| Vol. 8.03 – 28 January, 2022 |
| |
|
|
| Researchers showed that TNF-independent intestinal epithelial cells death after A20 and Abin-1 deletion was rescued by germ-free derivation or deletion of MyD88, while deletion of Trif provided only partial protection. [Journal of Clinical Investigation] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors investigated the impact of oncogenic transformation and the microenvironment on tumor cell invasion using genetically engineered organoids as colorectal cancer models. [Oncogene] |
|
|
|
| Researchers investigated the role of the NFE2L3 transcription factor in inflammation-induced colorectal cancer. [Oncogene] |
|
|
|
| NR2F1-AS1 and NR2F1 were highly co-expressed in pan-tissues and pan-cancers. Depletion of NR2F1-AS1 compromised the expression level of NR2F1 in gastric cancer cells. [Cell Death & Disease] |
|
|
|
| Researchers addressed the contribution of posttranscriptional regulation, by the RNA-binding protein CPEB4, to intestinal immune homeostasis and its role in inflammatory bowel diseases and CRC development. [iScience] |
|
|
|
| The authors first found that glycyrrhizin (GL) bound to the first PDZ domain of zonula occludens-1 through NMR experiments. They identified the relevant interactions between the glucuronate-2 moiety of GL and the carboxylate binding loop of the ligand binding site of ZO-1(PDZ1). [Food & Function] |
|
|
|
| Researchers evaluated combination therapy with MEK inhibitor selumetinib and MDM2 inhibitor KRT-232 in TP53 wild-type and mitogen-activated protein kinase (MAPK) altered colon and thyroid cancer models. [Scientific Reports] |
|
|
|
| The molecular properties and the effects of principal parameters were analyzed by liquid chromatography-tandem mass spectrometry. [Journal of Ethnopharmacology] |
|
|
|
| Scientists assessed the effect of citrus flavonoids and their intestinal metabolites on immune-mediated barrier disruption in an in vitro co-culture model. [British Journal of Nutrition] |
| |
|
|
|
| The authors reviewed the recent progress of this signal transduction pathway in colorectal tumorigenesis. [Biochimie] |
|
|
|
|
| Zealand Pharma A/S announced completion of patient enrollment in its pivotal Phase III trial of glepaglutide, the company’s long-acting GLP-2 analog, for the potential treatment of short bowel syndrome. [Zealand Pharma A/S (GlobeNewswire, Inc.)] |
|
|
|
|
| March 9 – 11, 2022 Melbourne, Victoria, Australia |
|
|
|
|
|
| The University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
| University of Oxford – Oxford, England, United Kingdom |
|
|
|
| University of North Dakota – Grand Forks, North Dakota, United States |
|
|
|
| Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
|